Skip to main content
Premium Trial:

Request an Annual Quote

Geisinger Teams With Medial EarlySign for AI-based Flagging of High-Risk Patients

NEW YORK – Geisinger Health System's Steele Institute for Health Innovation is teaming with Israeli healthcare software company Medial EarlySign to develop machine-learning technologies for identification of patients at risk of "high-burden" and chronic diseases.

The new partners said today that the Steele Institute will use Medial EarlySign's LGI-Flag software to analyze changes in blood test values and electronic health records data to flag patients who might be at elevated risk for lower gastrointestinal disorders. EarlySign and Danville, Pennsylvania-based Geisinger also will look to extend the technology to other acute and chronic diseases.

"EarlySign's technology and the LGI-Flag solution will potentially assist our teams to more quickly identify significant lower GI disorders and intervene earlier than we historically have been able to," Keith Boell, associate chief quality officer at Geisinger, said in a statement.

"This collaboration will help us potentially save lives and improve the care we provide patients by deepening our experience with [artificial intelligence] and identifying new ways to integrate it into daily clinical care," added Geisinger Chief Innovation Officer Karen Murphy.

EarlySign, of Tel Aviv, developed LGI-Flag to look for lower GI disorders associated with chronic occult bleeding. Other EarlySign technology is helping healthcare providers identify patients with elevated risk of prediabetic progression to diabetes, diabetic complications, coronary artery disease, and chronic kidney disease, the company said.